Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988864 | 0.91 | L3MBTL1 (0.63) | SMN1; SMN2NAMPTGAAADORA2AMAPT | |
| SCHEMBL5540070 | 0.90 | NAMPT (0.73) | SMN1; SMN2NAMPTGAAHDAC3MCHR1 | |
| SCHEMBL19133524 | 0.86 | NAMPT (0.61) | SMN1; SMN2NAMPTGAAADORA2AHDAC3 | |
| SCHEMBL17623594 | 0.86 | HDAC3 (0.63) | SMN1; SMN2NAMPTGAAADORA2AMAPT | |
| SCHEMBL21610884 | 0.85 | NAMPT (0.56) | SMN1; SMN2NAMPTGAAADORA2AMAPT | |
| SCHEMBL6203164 | 0.85 | GPR139 (0.57) | SMN1; SMN2NAMPTGAAHDAC3MCHR1 | |
| SCHEMBL7556161 | 0.85 | NAMPT (0.58) | SMN1; SMN2NAMPTGAAHDAC3MCHR1 | |
| SCHEMBL16117373 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAMAPTNAAAL3MBTL1 | |
| SCHEMBL1927040 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NAMPTGAAMAPTNAAA | |
| SCHEMBL13578974 | 0.83 | NAMPT (0.56) | SMN1; SMN2NAMPTGAAADORA2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | SMN1; SMN2 3865/4885NAMPT 3813/4885GAA 1880/4885 |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | SMN1; SMN2 4165/4885NAMPT 1736/4885GAA 1077/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | SMN1; SMN2 3865/4885NAMPT 3813/4885GAA 1880/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | SMN1; SMN2 3143/4885NAMPT 1853/4885GAA 2016/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885NAMPT 382/4885GAA 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.